Point72 Asia (Singapore)’s DiaMedica Therapeutics DMAC Stock Holding History

Point72 Asia (Singapore)’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,480	Closed	-$47.3K	–	973
2025 Q1	$47.3K	Buy	+12,480	New	+$71.4K	0.01%	581
2024 Q4	–	Sell	-9,498	Closed	-$39.8K	–	948
2024 Q3	$39.8K	Buy	+9,498	New	+$35.1K	0.01%	726

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asia (Singapore)'s DMAC Position: Q2 2025 in Review

Point72 Asia (Singapore) sold out of DiaMedica Therapeutics (DMAC) in Q2 2025, closing a stake of 12,480 shares — an estimated $47.3K sold.

Point72 Asia (Singapore) first reported a position in DMAC in Q3 2024 and held it in 2 quarters. The position peaked at $47.3K in Q1 2025. 58 funds tracked by Wall St. Rank hold DMAC as of Q2 2025.

Point72 Asia (Singapore) reported no remaining DiaMedica Therapeutics position as of Q2 2025 after selling out during the quarter.
Point72 Asia (Singapore) sold 12,480 DiaMedica Therapeutics shares in Q2 2025, an estimated $47.3K.
Point72 Asia (Singapore) first reported a position in DiaMedica Therapeutics in Q3 2024 and held it in 2 quarters.
Point72 Asia (Singapore)'s DiaMedica Therapeutics position peaked at $47.3K in Q1 2025.
58 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2025, filed 14 Aug 2025.